בוסטריקס פוליו
glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn or 69 kda omp); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml; diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid vaccine 8 mcg / 0.5 ml; inactivated polio virus (ipv) type 3 32 du / 0.5 ml; inactivated polio virus (ipv) type 1 40 du / 0.5 ml; inactivated polio virus (ipv) type 2 8 du / 0.5 ml - bacterial and viral vaccines, combined - for booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of four years onwards. boostrix polio is not intended for primary immunisation. the administration of boostrix polio should be based on official recommendations.
איקסיארו
kamada ltd, israel - japanese encephalitis purified inactivated vaccine - תרחיף להזרקה - japanese encephalitis purified inactivated vaccine 6 au / 0.5 ml - encephalitis, japanese, inactivated, whole virus
אדסל פוליו
sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 3 years and over as a booster following primary immunisation . adacel polio is not indicatd for primary immunisation. adacel polio is not indicated for treating diseases caused by b. pertussis, c.diphtheriae or c. tetani or by poliomyelitis infections.
אימווקס פוליו
sanofi israel ltd - poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated - תרחיף להזרקה - poliovirus type 1 inactivated 40 u/vial; poliovirus type 2 inactivated 8 u/vial; poliovirus type 3 inactivated 32 u/vial - poliomyelitis vaccines - prophylaxis of poliomyelitis.
אינפנריקס הקסא
glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b.
הקסקסים
sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; hepatitis b vaccines; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus protein conjugate; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid; tetanus protein conjugate 22 - 36 mcg / 0.5 ml; haemophilus influenzae type b polysaccharide 12 mcg / 0.5 ml; hepatitis b vaccines 10 mcg / 0.5 ml; poliovirus type 3 inactivated 32 du / 0.5 ml; poliovirus type 2 inactivated 8 du / 0.5 ml; poliovirus type 1 inactivated 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus-hepatitis b
פלומיסט קואדריוואלנט
astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.
וקסיגריפ
medici medical ltd, israel - a/michigan/45/2015 (h1n1)pdm09-like virus; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) - תרחיף להזרקה - b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) 15 mcg/dose; a/michigan/45/2015 (h1n1)pdm09-like virus 15 mcg/dose; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 15 mcg/dose; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg/dose - influenza, inactivated, whole virus - influenza, inactivated, whole virus - for the prevention of influenza.
אינפלובאק
abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - תרחיף להזרקה - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.
אווקסים 160 u
medici medical ltd, israel - hepatitis a vaccines - תרחיף להזרקה - hepatitis a vaccines 160 au / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - for active immunisation against infection caused by hepatitis a virus in adults and adolescents over the age of 15